Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Cash from Operations (2020 - 2025)

Tango Therapeutics has reported Cash from Operations over the past 6 years, most recently at 29718000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 29718000.0 for Q4 2025, up 18.91% from a year ago — trailing twelve months through Dec 2025 was 138886000.0 (down 5.62% YoY), and the annual figure for FY2025 was 138886000.0, down 5.62%.
  • Cash from Operations for Q4 2025 was 29718000.0 at Tango Therapeutics, up from 30952000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for TNGX hit a ceiling of 7518000.0 in Q2 2021 and a floor of 41697000.0 in Q1 2025.
  • Median Cash from Operations over the past 5 years was 29691500.0 (2022), compared with a mean of 27848800.0.
  • Biggest five-year swings in Cash from Operations: crashed 23493650.0% in 2021 and later rose 22.4% in 2023.
  • Tango Therapeutics' Cash from Operations stood at 16902000.0 in 2021, then crashed by 67.23% to 28266000.0 in 2022, then increased by 2.83% to 27467000.0 in 2023, then tumbled by 33.42% to 36647000.0 in 2024, then grew by 18.91% to 29718000.0 in 2025.
  • The last three reported values for Cash from Operations were 29718000.0 (Q4 2025), 30952000.0 (Q3 2025), and 36519000.0 (Q2 2025) per Business Quant data.